Evidence map›Paper›PMID 32937800›Full record

ArticleJournal of clinical medicine2020

Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19.

Luigi Brunetti, Oumou Diawara, Andrew Tsai, Bonnie L Firestein, Ronald G Nahass, George Poiani, Naomi Schlesinger

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 14 pooled it
1.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 14 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Colchicine, COVID-19 and hematological parameters: A meta-analysis.Journal of clinical laboratory analysis · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Impact of colchicine on mortality in patients with COVID-19: A meta-analysis.Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
    Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Luigi BrunettiRobert Wood Johnson University Hospital Somerset, 110 Rehill Avenue, Somerville, NJ 08876, USA.ORCID 0000-0003-0565-6167
Oumou DiawaraRobert Wood Johnson University Hospital Somerset, 110 Rehill Avenue, Somerville, NJ 08876, USA.
Andrew TsaiRobert Wood Johnson University Hospital Somerset, 110 Rehill Avenue, Somerville, NJ 08876, USA.
Bonnie L FiresteinDepartment of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Ronald G NahassRobert Wood Johnson University Hospital Somerset, 110 Rehill Avenue, Somerville, NJ 08876, USA.
George PoianiRobert Wood Johnson University Hospital Somerset, 110 Rehill Avenue, Somerville, NJ 08876, USA.ORCID 0000-0001-9983-0386
Naomi SchlesingerDivision of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
Somerset Medical Center · USRutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25-20.1;

Indexed as

colchicinecoronavirusCOVID-19cytokine stormviral pneumonia

Identifiers

PMID32937800
PMCPMC7565543
OpenAlexW3086380010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.